To evaluate the Safety and efficacy of Unani formulations in the treatment of Dry Cough

Phase 2

Recruiting

• Conditions: Cough, Surfa YÄbis (Dry Cough),

• Registration Number: CTRI/2015/02/005526
• Lead Sponsor: Monetary Support Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Surfa YÄbis (Dry Cough)** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically every week.  This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 02 weeks. . Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Compositionof** ***Sharbat Ejaz***



| | | | |

| --- | --- | --- | --- |

| **S. No.**

**Ingredients**

**Botanical / Chemical Name**

**Quantity**



| 1.

Barg-e-Arusa

*Adhatoda vasica*

500 g



| 2.

Unnab

*Zyzifus sativa*

50 g



| 3.

Sapistan

*Cordia latifolia*

50 g



| 4.

Asl-us-Soos

*Glycyrrhiza glabra*

25 g



| 5.

Tukhm-e-Khatmi

*Althaea officinalis*

25 g



| 6.

Tukhm-e-Khubazi

*Malva sylvestris*

25 g



| 7.

Gul-e-Neelofar

*Nymphaea alba*

25 g



| 8.

Gul-e-Banafsha

*Viola odorata*

25 g



| 9.

Behidana

*Cydonia oblonga*

20 g



| 10.

Kateera

*Astragalus gummifer*

10 g



| 11.

Samag-e-Arabi

*Acacia arabica*

10 g



| 12.

Qand Safaid

*Saccharaum officinale*

1 kg



| 13.

Aab

*Oxidane (Water)*

Q.S.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-02
• Last Update Posted: 2018-03-12

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

•Patients of either sex in the age group of 18-60 •Surfa YÄbis (Dry Cough) of < 3 weeks duration.

Exclusion Criteria

• •Upper Respiratory Tract Infections (URI or URTI) including rhinitis, rhinosinusitis or sinusitis, nasopharyngitis (rhinopharyngitis or common cold), pharyngitis tonsillitis, epiglottitis (supraglottitis), laryngitis, laryngotracheitis, tracheitis, and otitis media.
• •Lower Respiratory Tract Infections (LRI or LRTI) including pneumonia, lung abscess, and acute bronchitis.
• •Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema.
• •Bronchiectasis, pulmonary tuberculosis, pulmonary oedema, interstitial pulmonary fibrosis •Tumours of larynx, bronchi, and lungs •Drug-induced Cough (e.g., ACE Inhibitors) •Diabetes Mellitus, Hypertension •Known cases of severe hepatic, renal or cardiac ailments •H/o addiction (smoking, alcohol, drugs) •Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms	2 weeks

Secondary Outcome Measures

Name	Time	Method
Hematological and biochemical assessments for safety	2 weeks

Trial Locations

Locations (4)

Clinical Research Unit, Meerut; 🇮🇳 Meerut, UTTAR PRADESH, India

Regional Research Institute of Unani Medicine (RRIUM), Mumbai; 🇮🇳 Mumbai, MAHARASHTRA, India

Regional Research Institute of Unani Medicine(RRIUM), New Delhi; 🇮🇳 South, DELHI, India

Regional Research Institute of Unani Medicine(RRIUM), Srinagar; 🇮🇳 JAMMU, & KASHMIR, India

Clinical Research Unit, Meerut

🇮🇳Meerut, UTTAR PRADESH, India

DR MOHD TARIQ KHAN

Principal investigator

09012843253

doctormtk@gmail.com